

Anemia of Chronic Kidney Disease

Failing kidneys cannot make enough erythropoietin, so the bone marrow starves for the signal it needs to produce red blood cells.

THE STORY IN ONE SENTENCE

Failing kidneys cannot make enough erythropoietin, so the bone marrow starves for the signal it needs to produce red blood cells.

“Anemia of chronic kidney disease happens when damaged kidneys stop making enough erythropoietin, a hormone that tells bone marrow to make red blood cells. Without this signal, red blood cell production drops and the patient becomes anemic even though the marrow itself is healthy.”

Normal anatomy — the body's job

Healthy kidneys contain special cells in the outer part (cortex) that sense oxygen levels in the blood. When oxygen drops even slightly, these cells release erythropoietin (EPO), a hormone that travels through the bloodstream to the bone marrow. EPO binds to receptors on early red blood cell precursors (stem cells) in the marrow and triggers them to multiply and mature into red blood cells, keeping the oxygen-carrying capacity of blood steady.

BODY'S JOB

The kidney acts like a factory supervisor checking the oxygen supply on the factory floor—when it notices the oxygen is running low, it sends out a work order (erythropoietin) to the bone marrow factory to ramp up production of red blood cell workers.

1. Kidney cells constantly measure oxygen levels in blood flowing through tiny vessels
2. When oxygen drops, kidney cells activate the HIF (hypoxia-inducible factor) pathway inside them
3. HIF tells the cell's DNA to make erythropoietin (EPO) hormone
4. EPO is released into the bloodstream and travels to the bone marrow
5. EPO binds to receptors on early red blood cell precursors in the marrow
6. These precursors multiply and mature into millions of new red blood cells that enter circulation

What breaks

When kidney disease progresses, the oxygen-sensing cells in the kidney die or become scarred and stop working. These damaged cells can no longer detect low oxygen or produce erythropoietin in the amounts needed. The bone marrow is still healthy and capable, but without the hormone signal, it does not know to increase red blood cell production, so anemia develops.

CLINICAL TERM

Chronic kidney disease causes tubulointerstitial fibrosis (scarring of the kidney tissue between tubules) that destroys peritubular fibroblasts (specialized cells around kidney tubules) responsible for EPO synthesis. Additionally, severe waste buildup in the blood (uremia) (buildup of waste products in the blood) shortens red blood cell lifespan and causes mild bone marrow suppression, compounding the anemia from EPO deficiency.

How the body compensates

The body tries to compensate for low red blood cell counts by increasing cardiac output (the heart pumps more blood per minute) and shifting the oxygen-hemoglobin dissociation curve to release oxygen more easily to tissues. However, these adaptations cannot fully overcome severe EPO deficiency, and symptoms of anemia eventually appear.

1. {'step': 'Heart increases stroke volume and heart rate', 'detail': 'The heart pumps harder and faster to circulate the fewer red cells more quickly, delivering oxygen despite lower red cell numbers'}
2. {'step': 'Increased 2,3-DPG in red cells', 'detail': 'Red cells make more 2,3-diphosphoglycerate (2,3-DPG), a chemical that makes hemoglobin release oxygen more easily to tissues'}
3. {'step': 'Blood flow redistributed to vital organs', 'detail': 'Blood vessels constrict in skin and non-essential areas to send more blood to the brain and heart'}
4. {'step': 'Increased plasma volume', 'detail': 'The body retains more fluid to increase total blood volume, partially compensating for low red cell mass'}
5. {'step': 'Respiratory rate increases', 'detail': 'Breathing rate goes up to load more oxygen into the fewer red cells available'}
6. {'step': 'Marrow attempts increased output from remaining EPO', 'detail': 'The bone marrow responds to whatever small amount of EPO remains, but this is inadequate when kidney function is very low'}

Domino effect

1. Chronic kidney disease damages peritubular fibroblasts — Ongoing kidney injury causes fibrosis and inflammation that destroys the cells responsible for making erythropoietin
2. Erythropoietin production drops below normal levels — With fewer functional EPO-producing cells, total EPO output declines even when the body senses low oxygen
3. Bone marrow receives inadequate stimulation — Low EPO levels mean fewer signals reach red cell precursors in the marrow, slowing down their multiplication and maturation
4. Red blood cell production falls and hemoglobin drops — The marrow makes fewer red cells, and existing cells age out of circulation, causing anemia to develop gradually
5. Tissue oxygen delivery decreases — Fewer red cells mean less hemoglobin available to carry oxygen from lungs to organs and muscles
6. Compensatory mechanisms activate but prove insufficient — The heart works harder and breathing increases, but these cannot fully replace the oxygen-carrying capacity lost from low red cell mass
7. Left ventricular hypertrophy (thickening of the heart muscle) develops — Chronic increased cardiac workload causes the heart muscle to thicken, raising the risk of heart failure and arrhythmias (irregular heartbeats)
8. Progressive fatigue, exercise intolerance, and increased cardiovascular mortality — Severe anemia overworks the heart, worsens kidney disease through poor oxygen delivery, and increases the risk of heart attack, stroke, and death

Symptoms · what the patient feels, and why

- Fatigue and weakness: Low hemoglobin (oxygen-carrying protein in red blood cells) reduces oxygen delivery to muscles and brain
- Shortness of breath with mild activity: Heart and lungs work harder to deliver oxygen when red blood cell count is low
- Pale skin and mucous membranes: Fewer red blood cells in small blood vessels under the skin reduces normal pink color
- Dizziness or lightheadedness: Brain receives less oxygen when standing or moving quickly due to low hemoglobin
- Cold hands and feet: Body prioritizes oxygen delivery to vital organs, reducing blood flow to extremities
- Chest pain or pressure: Heart muscle demands more oxygen but anemia reduces oxygen supply, especially in patients with existing heart disease
- Rapid or irregular heartbeat: Heart rate increases to compensate for reduced oxygen-carrying capacity in severe anemia

- Confusion or difficulty concentrating: Brain function declines when oxygen delivery falls below critical threshold due to severe anemia

Focused exam

- Conjunctival pale skin (pallor) (pale color inside lower eyelid): Reliable physical sign of anemia that correlates with hemoglobin below 9 g/dL when pronounced
- A fast heart rate (Tachycardia) (heart rate above 100) at rest: Indicates heart is compensating for reduced oxygen-carrying capacity and suggests hemoglobin may be dangerously low
- Flow murmur (soft whooshing sound) heard over the heart: Thin blood from severe anemia creates turbulent flow; murmur disappears when anemia is corrected
- Orthostatic vital signs (blood pressure and pulse measured lying and standing): Drop in blood pressure or rise in pulse when standing suggests reduced blood volume from bleeding or severe anemia affecting circulation
- Peripheral swelling (edema) (swelling in legs and ankles): May indicate fluid overload from kidney disease or heart failure worsened by anemia stressing the cardiovascular system
- Signs of heart failure (crackles in lungs, jugular vein distension in neck): Severe anemia increases cardiac workload and can trigger acute heart failure requiring immediate treatment

Diagnostics · every test answers a question

- Complete blood count (CBC) with red cell indices → What is the hemoglobin level and are red blood cells normal size and color?
- Reticulocyte count (young red blood cells) → Is the bone marrow responding appropriately by making new red blood cells?
- Serum ferritin (iron storage protein) and transferrin saturation (TSAT) → Are iron stores adequate to support red blood cell production?
- Serum creatinine and estimated glomerular filtration rate (eGFR) → How severely is kidney function impaired?
- Vitamin B12 and folate levels → Could vitamin deficiency be contributing to anemia?
- Stool occult blood test → Is hidden gastrointestinal bleeding worsening the anemia?
- C-reactive protein (CRP) or red blood cell (erythrocyte) sedimentation rate (ESR) → Is inflammation blocking response to erythropoietin treatment?
- Parathyroid hormone (PTH) level → Is secondary hyperparathyroidism (overactive parathyroid glands from kidney disease) worsening anemia?

Treatment logic

- Erythropoiesis-stimulating agents (ESAs) → Replace missing kidney hormone to stimulate bone marrow production of red blood cells, raising hemoglobin to target range of 10-11.5 g/dL per KDIGO guidelines
- Intravenous iron supplementation → Replenishes iron stores needed for hemoglobin synthesis, especially functional iron deficiency where inflammation blocks iron use despite adequate total body stores
- Treat underlying kidney disease and complications → Control blood pressure, manage diabetes, reduce proteinuria (protein in urine) to slow kidney decline; treat hyperparathyroidism to reduce bone marrow suppression
- Red blood cell transfusion → Immediately raises hemoglobin and oxygen-carrying capacity in life-threatening anemia or acute cardiac symptoms
- Low oxygen (Hypoxia)-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) → Newer oral medications that activate body's natural response to low oxygen, increasing erythropoietin production and improving iron use from stores
- Dietary protein optimization and phosphate management → Ensures adequate amino acids (protein building blocks) for hemoglobin production while avoiding excess that worsens severe waste buildup in the blood (uremia); controls phosphate to prevent bone disease worsening anemia

Medications

epoetin alfa · Erythropoiesis-stimulating agent (ESA)

This is a manufactured copy of erythropoietin, the hormone healthy kidneys make to tell bone marrow to produce red blood cells. It binds to receptors (docking stations) on immature red blood cells in bone marrow. This signal turns on genes that make the cells multiply and mature into functional red blood cells that carry oxygen.

1. Drug binds to erythropoietin receptor on surface of CFU-E cells (colony-forming unit-erythroid, committed red blood cell precursors) in bone marrow
2. Receptor activation triggers JAK2-STAT5 pathway (chemical signaling chain) inside the cell
3. Signal moves to cell nucleus and turns on genes for cell division and hemoglobin production
4. Cells divide and mature through normoblast (developing red blood cell) stages over 5-7 days
5. Mature red blood cells are released into bloodstream, raising hemoglobin level over 2-6 weeks

SAFETY WATCH

Target hemoglobin 10-11.5 g/dL per KDIGO 2012 guidelines; higher targets increase stroke, heart attack, and death risk · Check blood pressure before each dose; ESAs can raise blood pressure and cause with high blood pressure (hypertensive) emergency · Monitor iron studies monthly; treatment will fail if ferritin below 100 ng/mL or transferrin saturation below 20% · Watch for pure red cell aplasia (complete bone marrow shutdown) if patient stops responding after initial success

darbepoetin alfa · Long-acting erythropoiesis-stimulating agent (ESA)

This is a modified version of erythropoietin with extra sugar molecules attached that make it last longer in the body. It works the same way as natural erythropoietin by stimulating bone marrow to make red blood cells. The longer half-life (time in body before breaking down) means it can be given less frequently than epoetin alfa, usually once weekly or every two weeks.

1. Drug binds to erythropoietin receptor with same mechanism as natural erythropoietin
2. Extra sialic acid (sugar) groups protect drug from kidney clearance and enzyme breakdown
3. Receptor activation triggers same JAK2-STAT5 signaling pathway as epoetin
4. Prolonged blood levels maintain steady stimulation of red blood cell production
5. Hemoglobin rises gradually over 2-6 weeks with less frequent dosing needed

SAFETY WATCH

Same hemoglobin targets as epoetin alfa; maintain 10-11.5 g/dL per KDIGO guidelines · Monitor blood pressure with each dose adjustment · Risk of clot formation (thrombosis) (blood clots) increases if hemoglobin rises too quickly (more than 1 g/dL per 2 weeks) · Check response after 4 weeks; if no increase in hemoglobin or reticulocytes, evaluate for iron deficiency, bleeding, or ESA resistance

iron sucrose · Intravenous iron replacement

This is iron surrounded by a sucrose (sugar) shell that protects it in the bloodstream. Macrophages (cleanup cells) in the liver and spleen take up the iron-sucrose complex and slowly release iron into the body's storage pool. From storage, iron moves to bone marrow where it is inserted into hemoglobin molecules being made inside developing red blood cells. Intravenous iron bypasses the gut absorption problems common in kidney disease.

1. Iron sucrose complex is taken up by macrophages in liver and spleen within minutes of infusion

2. Macrophages break down sucrose shell and release elemental iron slowly over days to weeks
3. Released iron binds to transferrin protein in blood for transport to bone marrow
4. Transferrin delivers iron to erythroblasts where it is inserted into protoporphyrin rings to make heme (oxygen-binding part of hemoglobin)
5. Adequate iron allows ESAs to work effectively and hemoglobin production to proceed normally

SAFETY WATCH

Monitor for anaphylaxis (severe allergic reaction) during and 30 minutes after each infusion; have epinephrine ready · Do not give during active infection; iron can fuel bacterial growth · Target ferritin 200-500 ng/mL and transferrin saturation 30-50% per KDIGO; excess iron increases infection and cardiovascular risk · Watch for low blood pressure (hypotension) (low blood pressure) if infused too rapidly; follow facility protocols for infusion rate

ferric carboxymaltose · Intravenous iron replacement (high-dose formulation)

This is iron bound to a carbohydrate shell that is very stable in blood, allowing large doses to be given in a single infusion. The complex is taken up by macrophages and iron is released into storage pools over weeks. This formulation allows rapid repletion of iron stores without the frequent dosing required by older intravenous iron products. It works the same way as other IV iron once released into the body's iron pool.

1. Stable ferric carboxymaltose complex circulates in blood with minimal immediate iron release
2. Macrophages gradually take up the complex over hours to days after infusion
3. Carbohydrate shell is metabolized and iron is released into ferritin (storage protein) pools
4. Iron moves from storage to transferrin for delivery to bone marrow as needed
5. Sustained iron availability supports red blood cell production over several weeks from single dose

SAFETY WATCH

Check serum phosphate 2-4 weeks after infusion; this formulation can cause severe hypophosphatemia requiring replacement · Monitor for hypersensitivity reactions during infusion; risk lower than iron dextran but still present · Do not exceed total calculated iron deficit; overdose increases oxidative stress and infection risk · Avoid in first trimester of pregnancy; safety data limited

roxadustat · Low oxygen (Hypoxia)-inducible factor prolyl hydroxylase inhibitor (HIF-PHI)

This oral medication blocks enzymes that normally break down HIF (hypoxia-inducible factor), a protein that controls the body's response to low oxygen. When HIF accumulates, it turns on multiple genes including the erythropoietin gene in kidney cells and genes that improve iron absorption from the gut and iron release from storage. This mimics the body's natural adaptation to high altitude or low oxygen conditions.

1. Drug inhibits prolyl hydroxylase enzymes that normally tag HIF protein for destruction
2. Stabilized HIF protein moves into cell nucleus and binds to low oxygen (hypoxia) response elements (gene control regions)
3. HIF activates erythropoietin gene in kidney cells, increasing natural erythropoietin production in pulsatile pattern
4. HIF also reduces hepcidin (hormone that blocks iron release) and increases ferroportin (iron export protein), mobilizing stored iron
5. Combined effects of increased erythropoietin and improved iron availability raise red blood cell production and hemoglobin

SAFETY WATCH

Monitor potassium levels; drug can cause high potassium (hyperkalemia) (high potassium) requiring dietary restriction or binders · Check blood pressure regularly; can increase blood pressure like ESAs · Avoid in patients with recent stroke, unstable heart disease, or active cancer due to theoretical tumor growth concerns from HIF activation · Requires dose adjustment based on hemoglobin response; monitor every 4 weeks initially

packed red blood cell transfusion · Blood product replacement therapy

This is not a medication but a biological product containing concentrated red blood cells from donors. Each unit immediately adds functional red blood cells to circulation, raising hemoglobin by approximately 1 g/dL per unit in average adult. Transfused cells survive 28-35 days in circulation before being removed by the spleen. This provides rapid correction of oxygen-carrying capacity in severe or symptomatic anemia while waiting for other treatments to work.

1. Donor red blood cells are type-matched and cross-matched to patient to prevent immune reactions
2. Transfused cells enter circulation during infusion and immediately begin carrying oxygen
3. Hemoglobin level rises within hours of completing transfusion
4. Transfused cells function normally for weeks until removed by splenic macrophages

5. Temporary hemoglobin elevation maintains oxygen delivery while ESAs and iron begin working over weeks

SAFETY WATCH

Reserve for hemoglobin below 7 g/dL or symptomatic anemia with chest pain, heart failure, or inability to function per KDIGO guidelines · Monitor for transfusion reactions including fever, chills, and severe allergic reactions during infusion · Each unit adds 200-250 mg of iron to body stores; multiple transfusions lead to iron overload requiring chelation therapy · Antibody formation from transfusions increases rejection risk if patient later needs kidney transplant; minimize transfusions in transplant candidates

Red flags

- Hemoglobin below 7 g/dL with chest pain or shortness of breath suggests cardiac starved blood flow (ischemia) requiring urgent transfusion
- Black tarry stools or bright red blood in stool indicates active GI bleeding requiring endoscopy before anemia treatment
- Sudden drop in hemoglobin of 2 g/dL or more in 2 weeks suggests acute bleeding or red blood cell destruction (hemolysis) needing immediate workup
- New heart failure symptoms with anemia require urgent treatment as severe anemia can trigger cardiogenic shock

Nursing priorities

1. Monitor hemoglobin (oxygen-carrying protein in blood) and hematocrit (percentage of blood made up of red blood cells) levels regularly — Chronic kidney disease (CKD) causes anemia by reducing erythropoietin (kidney hormone that signals bone marrow to make red blood cells) production; tracking levels guides treatment adjustments and prevents severe anemia complications like heart failure
2. Assess for signs of tissue low oxygen (hypoxia) (low oxygen in body tissues) including fatigue, shortness of breath, chest pain, and confusion — Anemia reduces oxygen delivery to vital organs; early recognition prevents dangerous complications like heart attack (myocardial infarction) (heart attack), stroke, and cognitive decline
3. Administer erythropoiesis-stimulating agents (ESAs) such as epoetin alfa or darbepoetin alfa as prescribed — ESAs replace the missing kidney hormone that stimulates red blood cell production; proper administration corrects anemia and improves quality of life while avoiding overtreatment that increases stroke and clot risk

4. Monitor and maintain adequate iron stores through serum ferritin (protein that stores iron) and transferrin saturation (TSAT) testing — Iron is required for red blood cell production; CKD patients often have functional iron deficiency (iron trapped in storage, unavailable for use) requiring supplementation for ESAs to work effectively
5. Educate patient about dietary protein and phosphorus balance while ensuring adequate nutrition — CKD requires protein restriction to reduce kidney workload, but severe restriction worsens anemia and malnutrition; balanced nutrition supports red blood cell production and overall health
6. Monitor blood pressure closely during ESA therapy — ESAs can cause or worsen high blood pressure (hypertension) (high blood pressure) by increasing blood thickness and vascular resistance; uncontrolled blood pressure increases stroke, heart attack, and kidney damage risk
7. Assess for bleeding risk and avoid unnecessary blood draws — Anemic patients have limited red blood cell reserves; excessive phlebotomy (blood drawing) worsens anemia, and bleeding complications are harder to tolerate with existing low hemoglobin
8. Coordinate care with nephrology and evaluate dialysis adequacy if patient is on renal replacement therapy — Inadequate dialysis worsens anemia through uremic toxin (waste product) accumulation that suppresses bone marrow and shortens red blood cell lifespan; optimal dialysis improves anemia management

Sources

- Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. *Kidney International Supplements*. 2012;2(4):279-335
- National Kidney Foundation. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease: 2007 Update of Hemoglobin Target. *American Journal of Kidney Diseases*. 2007;50(3):471-530
- American Society of Hematology 2023 Guidelines for Management of Anemia in Chronic Kidney Disease
- Centers for Disease Control and Prevention (CDC). Chronic Kidney Disease in the United States, 2023. National Chronic Kidney Disease Fact Sheet

Last reviewed: 2026-08-29